FDA advisors approve Pfizer's RSV vaccine for infants with safety concerns.

A committee of independent expert advisors for the FDA voted largely in favor of approving Pfizer's vaccine for protecting infants from the common respiratory virus RSV. The vaccine, provisionally dubbed Abrysvo, is given to pregnant people between 24 and 36 weeks of pregnancy, allowing protective antibodies to develop and then cross the placenta to protect the fetus. The vaccine was nearly 82 percent effective at preventing severe RSV disease in the first 90 days of a baby's life. However, data from a phase II trial and the phase III trial included a faint signal suggesting the vaccination could increase the risk of pre-term birth.